AZ-628 sensitizes donafenib in hepatocellular carcinoma by targeting tyrosine kinase pathway and ferroptosis
The findings of this study reveal a new combination therapy targeting the TK pathway for the treatment of HCC and provide a theoretical foundation for addressing donafenib resistance.
Authors
- Chengyong Dong (ORCID: https://orcid.org/0000-0002-6461-8833)
- Tianyu Yu (ORCID: https://orcid.org/0000-0003-4450-3382)
- Zhenming Gao (ORCID: https://orcid.org/0009-0000-4734-5389)
- Yuhui Wang (ORCID: https://orcid.org/0000-0002-4167-2474)
- Hui Lu (ORCID: https://orcid.org/0000-0001-6875-6048)
- Xin Luo (ORCID: https://orcid.org/0000-0001-5446-4079)
- Xinyi Zhao (ORCID: https://orcid.org/0000-0002-5324-1137)
Institutions
- Dalian Medical University (CN)
- Second Affiliated Hospital of Dalian Medical University (CN)
- First Hospital of China Medical University (CN)
- Jinzhou Medical University (CN)
- China Medical University (CN)
Publication Details
- Journal
- CytoJournal
- Published
- 2025-10-23
- DOI
- https://doi.org/10.25259/cytojournal_273_2024
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00